BAIYUNSHAN PH announced that its controlling subsidiary, Tianxin Pharmaceutical, has passed the consistency evaluation for the quality and efficacy of injectable cefazolin sodium. In 2023, the sales of injectable cefazolin sodium in public hospitals in China reached 3.8 billion yuan. Tianxin Pharmaceutical has invested approximately 2.7202 million yuan in research and development for this project, with sales revenue of 6.1531 million yuan in 2023. Passing the consistency evaluation for generic drugs is beneficial for enhancing the market competitiveness of this product.
白云山：注射用头孢唑肟钠通过仿制药一致性评价
BAIYUNSHAN PH: Injectable cefazolin sodium passes the consistency evaluation for generic drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha